Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Starpharma Pooled Development - half year report and accounts

February 25th, 2004

Starpharma Pooled Development - half year report and accounts

Abstract:
The results for the half year include a 42% reduction in the operating loss of the economic entity during the period, compared with the corresponding period of the previous year. Whilst part of this improvement has resulted from the successful conversion of the former controlled entity Dendritic Nanotechnologies Ltd to a US incorporated associated entity (Dendritic Nanotechnologies, Inc), two thirds of the savings are attributable to reductions in expenditure by the Australian group, as set out in the report.

Source:
Starpharma

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project